An initial clinical trial with a new hypoglycemic sulfonylurea is described. In most patients, significant reductions in blood sugar and elevations of plasma insulin levels were produced throughout the day, by doses ranging from 2.5 to 15 mg. twice daily. The greatly enhanced activity compared to other sulfonylureas may be due to increased hydrophobic bonding to the receptor vicinity. Two patients developed hypoglycemic reactions. Transient elevations in transaminase levels were the only other toxic effect noted. Our results to date do not suggest that this compound is clinically advantageous to other orally active hypoglycemic agents.

This content is only available via PDF.